Research Article

Predictors of Impaired Glucose Regulation in Patients with Non-Alcoholic Fatty Liver Disease

Erifili Hatziagelaki,¹ Drosos E. Karageorgopoulos,² Athina Chounta,³ Anastasia Tsiavou,¹ Matthew E. Falagas,^{2,4,5} and George Dimitriadis¹

¹2nd Department of Internal Medicine, Research Institute and Diabetes Center, University of Athens Medical School, Attikon University Hospital, 12462 Athens, Greece

²Alfa Institute of Biomedical Sciences (AIBS), Marousi, 15123 Athens, Greece

³4th Department of Internal Medicine, University of Athens Medical School, Attikon University Hospital, 12462 Athens, Greece

⁴Department of Medicine, Henry Dunant Hospital, 11526 Athens, Greece

⁵Department of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA

Correspondence should be addressed to Erifili Hatziagelaki, erihat@otenet.gr

Received 15 June 2011; Accepted 11 July 2011

Academic Editor: Faidon Magkos

Copyright © 2012 Erifili Hatziagelaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Many patients with non-alcoholic fatty liver disease (NAFLD) have impaired glucose regulation or type 2 diabetes mellitus (DM). We investigated characteristics of NAFLD patients associated with hyperglycemia. **Methods.** During a 2-hour oral glucose tolerance test (OGTT), serum glucose and insulin were measured in 152 NAFLD patients. **Results.** 48.7% of NAFLD patients had hyperglycemia. Age (odds ratio (OR) = 1.08, 95% confidence interval (CI): 1.03–1.13), body mass index (BMI) (OR = 1.12, 95% CI: 1.01–1.25), and lower high-density lipoprotein cholesterol (HDL-C) (OR = 0.95, 95% CI: 0.92–0.98) proved to be independent predictors of hyperglycemia. After OGTT, 30 min insulin was lower in hyperglycemic patients (74.2 ± 49.7 versus $94.5 \pm 53.9 \mu\text{IU/mL}$, $P = 0.02$), while 90 min insulin (170.1 ± 84.6 versus $122.9 \pm 97.7 \mu\text{IU/mL}$, $P = 0.01$) and 120 min insulin (164.0 ± 101.2 versus $85.3 \pm 61.9 \mu\text{IU/mL}$, $P < 0.01$) were higher. **Conclusions.** NAFLD patients with higher BMI, lower HDL-C, or older age were more likely to have impaired glucose metabolism. An OGTT could be of value for early diagnosis of DM among this population.

1. Introduction

Non-alcoholic fatty liver disease is increasingly being identified in routine clinical practice [1]. Although the natural history of this disorder is variable, the presence of non-alcoholic fatty liver disease may lead to an adverse prognosis for some patients, due to liver-related disorders, as well as cardiovascular morbidity and mortality [2–4]. The pathogenesis of non-alcoholic fatty liver disease has been closely related to insulin resistance; this disorder frequently co-exists with impaired glucose tolerance (IGT) or type 2 diabetes mellitus [5–7]. The latter conditions, if present, have been associated with more severe liver disease and unfavorable prognosis [8–11].

Screening patients with non-alcoholic fatty liver disease for impaired glucose regulation or type 2 diabetes mellitus could help the earlier diagnosis and treatment of these conditions preventing their possible complications, such as cardiovascular diseases. The measurement of fasting plasma glucose is considered as the preferred initial screening test for the identification of hyperglycemia [12]. The sensitivity of this test can be variable depending on the population evaluated [13, 14]. However, it has not been clearly established, which of the patients with non-alcoholic fatty liver disease should further undergo an oral glucose tolerance test for the above-described purposes. In this regard, we sought to identify predictor characteristics for the presence of impaired glucose regulation or type 2 diabetes

in patients with non-alcoholic fatty liver disease and assess for potential differences in these patients regarding glucose metabolism.

2. Methods

We prospectively studied a cohort of patients who presented with elevated levels of serum aminotransferases at the outpatient hepatology clinic of Attikon University Hospital, in Athens, Greece, between June 2006 and September 2009, and was diagnosed with non-alcoholic fatty liver disease. The diagnosis of non-alcoholic fatty liver disease was based on the presence of hypertransaminasemia along with characteristic findings of fatty infiltration in liver ultrasonography ("bright liver" or hyperechoic appearance) and the exclusion of other possible causes of hypertransaminasemia, including alcoholic liver disease, adverse events of drugs, viral hepatitis, autoimmune disorders, and hereditary diseases affecting the liver.

The patients that were diagnosed with non-alcoholic fatty liver disease underwent an oral glucose tolerance test, unless they had a known prior history of diabetes or a fasting serum glucose ≥ 126 mg/dL. Specifically, 75 g of glucose were administered orally after an overnight fast. Serum glucose and insulin were measured in blood samples obtained through an indwelling peripheral vein cannula at time 0 and 30, 60, 90, and 120 min after the glucose challenge. Patients were classified as having normoglycemia (normal glucose values), impaired fasting glucose (IFG), IGT, or type 2 diabetes, according to the criteria endorsed by the American Diabetes Association [15]. Approval for the study was granted by the institutional review board.

2.1. Data Analysis. We grouped the non-alcoholic fatty liver disease patients into normoglycemic and hyperglycemic (IFG, IGT, or type 2 diabetes). We assessed for the presence of differences between the above 2 groups in the patient demographics, body mass index (BMI), and common laboratory tests. We also assessed for differences between the 2 groups in the levels of glucose and insulin obtained at the 5 time points specified above during the 75 g oral glucose tolerance test and the overall insulin response during the test. The overall insulin response was determined on the basis of the area under the curve (AUC) of insulin levels versus time, extracting the area corresponding to the baseline insulin level (net incremental insulin AUC). We used the trapezoid method to calculate the AUC. Finally, we calculated the updated homeostasis model assessment of insulin resistance (HOMA2-IR) index and assessed for differences between the 2 groups [16]. We used the independent samples *t*-test and the χ^2 -test to compare continuous and categorical variables, respectively. The variables of baseline patient characteristics with different distributions between the normoglycemic and hyperglycemic groups were entered in a stepwise, forward, binary logistic regression model to test for independent associations. *P* values lower than 0.05 were considered statistically significant. We used the SPSS version 15.0 (SPSS Inc., Chicago, ILL) as the software for the statistical analysis.

3. Results

A total of 152 Caucasian patients (52.0% females and 48% males) with non-alcoholic fatty liver disease, with mean $\pm$ standard deviation age of 50.1 ± 11.4 years were included in the study. According to the values of fasting serum glucose or serum glucose 2 hours after the 75 g oral glucose challenge, 78 of the 152 patients (51.3%) were normoglycemic, while 45 patients (29.6%) had IFG or IGT (21 and 41 patients, resp.), and 29 (19.1%) had type 2 diabetes (Figure 1).

In Table 1, we describe the baseline patient characteristics and common laboratory tests in non-alcoholic fatty liver disease patients with or without hyperglycemia. Age, BMI, high-density lipoprotein cholesterol (HDL-C), and serum albumin were the only variables that significantly differed between the 2 studied groups. In the multivariate analysis that included the above four variables as covariates, age (odds ratio: 1.08, 95% confidence interval: 1.03–1.13), BMI (odds ratio: 1.12, 95% confidence interval: 1.01–1.25), and HDL-C (odds ratio: 0.95, 95% confidence interval: 0.92–0.98) were found to be independently associated with the presence of hyperglycemia in patients with non-alcoholic fatty liver disease. Patients with hyperglycemia had greater age (53.0 ± 10.7 versus 47.3 ± 11.4 years, $P < 0.01$), higher BMI (30.5 ± 4.5 versus 28.5 ± 4.8 kg/m², $P = 0.01$), lower HDL-C (46.5 ± 13.6 versus 53.7 ± 18.8 mg/dL, $P = 0.02$), and lower serum albumin (4.1 ± 0.5 versus 4.4 ± 0.4 g/dL, $P < 0.01$) in comparison to patients with normoglycemia (Figure 1).

Table 2 depicts the associations of serum glucose and insulin values obtained at time 0 and 30, 60, 90, and 120 min after the 75 g oral glucose load between non-alcoholic fatty liver disease patients with or without hyperglycemia. Patients with hyperglycemia (IFG, IGT, or type 2 diabetes) had higher glucose values at all the above-specified time points compared with patients without hyperglycemia. Additionally, patients with hyperglycemia showed significantly higher insulin levels at time 0, 90, and 120 min compared with patients without hyperglycemia. Insulin at 30 min was lower in the patients with hyperglycemia, and insulin at 60 min did not differ between the 2 groups. The overall insulin response (net incremental insulin AUC) did not differ, as well. The HOMA2-IR index significantly differed between the two groups (Table 2).

4. Discussion

Almost half (48.7%) of the patients with non-alcoholic fatty liver disease who were evaluated in our study and had IFG, IGT, or type 2 diabetes. This group was of older age had higher BMI, lower levels of HDL-C, and lower serum albumin compared with the group of patients without hyperglycemia. Age, BMI, and HDL-C were independent predictors of the presence of IFG, IGT, or type 2 diabetes in our cohort of patients with non-alcoholic fatty liver disease. The patients with hyperglycemia seemed to be more insulin resistant compared with those without hyperglycemia. The acute phase of insulin response to the 75 g oral glucose load was less pronounced in the hyperglycemic group, as evidenced by insulin at 30 min. This was followed by more

Fasting serum glucose	2-hour serum glucose after 75-g oral glucose challenge		
	Normal glucose tolerance	IGT	DM
Normal fasting glucose	78	33	16
IFG	4	8	9
DM	0	0	4

DM: type 2 diabetes mellitus, IFG: impaired fasting glucose, IGT: impaired glucose tolerance.

Cell shaded in white indicates the 78 patients with normoglycemia.

Cells shaded in light grey indicate the 45 patients with IFG or IGT.

Cells shaded in dark grey indicate the 29 patients with DM.

FIGURE 1: Classification of the 152 included patients with non-alcoholic fatty liver disease on the basis of fasting serum glucose and 2-hour post-load serum glucose.

TABLE 1: Baseline characteristics of non-alcoholic fatty liver disease patients with and without hyperglycemia.

Patient characteristics	IFG/IGT, <i>n</i> = 45	DM, <i>n</i> = 29	Hyperglycemia (IFG/IGT or DM), <i>n</i> = 74	Normoglycemia, <i>n</i> = 78	<i>P</i> value (patients with hyperglycemia versus normoglycemia)
n/N (%) OR mean ± standard deviation					
Sex, Female	21/45 (46.7%)	14/29 (48.3%)	35/74 (47.3%)	44/78 (56.4%)	0.26
Age, years	51.2 ± 10.2	55.9 ± 11.0	53.0 ± 10.7	47.3 ± 11.4	<0.01
Body mass index, kg/m ²	30.0 ± 4.2	31.1 ± 4.9	30.5 ± 4.5	28.5 ± 4.8	0.01
AST, U/L	43.7 ± 46.6	38.8 ± 23.5	41.7 ± 38.8	40.2 ± 33.4	0.81
ALT, U/L	64.6 ± 45.9	59.8 ± 39.1	62.7 ± 38.8	67.7 ± 55.6	0.55
AST/ALT ratio	0.68 ± 0.22	0.72 ± 0.30	0.70 ± 0.25	0.71 ± 0.39	0.85
GGT, U/L	86.7 ± 70.8	89.6 ± 87.1	87.9 ± 77.2	86.6 ± 88.7	0.92
Cholesterol, mg/dL	209.4 ± 40.7	209.2 ± 50.8	209.3 ± 44.6	211.9 ± 42.3	0.74
Triglycerides, mg/dL	135.1 ± 64.5	146.4 ± 76.2	139.7 ± 69.1	123.1 ± 72.3	0.18
HDL-C, mg/dL	47.6 ± 14.3	45.0 ± 12.7	46.5 ± 13.6	53.7 ± 18.8	0.02
LDL-C, mg/dL	128.3 ± 32.1	131.2 ± 40.3	129.6 ± 35.8	133.9 ± 34.1	0.51
Triglycerides/HDL-C ratio	3.6 ± 3.4	3.6 ± 2.2	3.6 ± 2.9	2.7 ± 2.2	0.05
Total Protein, g/dL	7.0 ± 1.5	7.0 ± 1.6	7.0 ± 1.5	7.1 ± 1.7	0.83
Albumin, g/dL	4.2 ± 0.4	4.0 ± 0.5	4.1 ± 0.5	4.4 ± 0.4	<0.01
Albumin/globulin ratio	3.1 ± 7.9	1.8 ± 1.7	2.5 ± 6.1	2.3 ± 3.1	0.83
Hemoglobin, g/dL	14.4 ± 1.5	13.6 ± 1.7	14.0 ± 1.6	14.1 ± 1.4	0.93
Hematocrit, %	43.4 ± 4.6	41.8 ± 4.2	42.7 ± 4.5	42.2 ± 3.8	0.45

ALT: alanine aminotransferase, AST: aspartate aminotransferase, DM: type 2 diabetes mellitus, IFG: impaired fasting glucose, IGT: impaired glucose tolerance, GGT: gamma-glutamyl transpeptidase, HDL-C: high-density lipoprotein cholesterol, IFG: impaired fasting glucose, and IGT: impaired glucose tolerance.

TABLE 2: Glucose and insulin regulation in response to a 75 g oral glucose tolerance test in non-alcoholic fatty liver disease patients with and without hyperglycemia.

Patient characteristics	IFG/IGT, <i>n</i> = 45	DM, <i>n</i> = 29	Hyperglycemia (IFG/IGT or DM), <i>n</i> = 74	Normoglycemia, <i>n</i> = 78	<i>P</i> value (patients with hyperglycemia versus normoglycemia)
	Mean $\pm$ standard deviation				
Glucose 0 min, mg/dL	89.9 $\pm$ 14.1	104.0 $\pm$ 21.9	95.4 $\pm$ 18.7	80.9 $\pm$ 10.5	<0.01
Insulin 0 min, μ IU/mL	15.4 $\pm$ 8.3	19.5 $\pm$ 10.2	17.0 $\pm$ 9.3	13.8 $\pm$ 7.2	0.02
Glucose 30 min, mg/dL	160.4 $\pm$ 27.0	179.9 $\pm$ 42.1	167.7 $\pm$ 34.6	147.8 $\pm$ 32.5	<0.01
Insulin 30 min, μ IU/mL	79.5 $\pm$ 53.4	65.3 $\pm$ 42.3	74.2 $\pm$ 49.7	94.5 $\pm$ 53.9	0.02
Glucose 60 min, mg/dL	204.5 $\pm$ 34.9	241.7 $\pm$ 40.3	219.1 $\pm$ 41.1	152.9 $\pm$ 39.0	<0.01
Insulin 60 min, μ IU/mL	133.1 $\pm$ 72.0	112.4 $\pm$ 70.7	125.0 $\pm$ 71.7	136.7 $\pm$ 88.8	0.38
Glucose 90 min, mg/dL	196.9 $\pm$ 37.4	264.1 $\pm$ 38.9	219.8 $\pm$ 49.4	126.9 $\pm$ 32.9	<0.01
Insulin 90 min, μ IU/mL	163.6 $\pm$ 80.0	183.0 $\pm$ 95.1	170.1 $\pm$ 84.6	122.9 $\pm$ 97.7	0.01
Glucose 120 min, mg/dL	163.2 $\pm$ 24.2	243.6 $\pm$ 38.3	194.7 $\pm$ 49.8	105.4 $\pm$ 21.7	<0.01
Insulin 120 min, μ IU/mL	160.9 $\pm$ 96.3	168.8 $\pm$ 110.1	164.0 $\pm$ 101.2	85.3 $\pm$ 61.9	<0.01
Net incremental insulin AUC, μ IU/mL * min	11872.9 $\pm$ 6608.2	10545.7 $\pm$ 6688.5	11352.8 $\pm$ 6626.1	10285.4 $\pm$ 6690.6	0.33
HOMA2-IR index	1.9 $\pm$ 1.0	2.5 $\pm$ 1.3	2.2 $\pm$ 1.2	1.7 $\pm$ 0.9	<0.01

AUC: area under the curve, HOMA2-IR: homeostasis model assessment of insulin resistance, DM: type 2 diabetes mellitus, IFG: impaired fasting glucose, IGT: impaired glucose tolerance, and LDL-C: low-density lipoprotein cholesterol.

pronounced hyperinsulinemia at 90 and 120 min after the glucose challenge.

Our study findings agree with those of other studies that have showed variability in the glucose regulation of patients with non-alcoholic fatty liver disease [10]. This could be in part attributed to the fact that non-alcoholic fatty liver disease comprises a spectrum of disorders of different severity, from simple hepatic steatosis to non-alcoholic steatohepatitis, hepatic fibrosis, and cirrhosis [6].

In our study, older age was associated with a greater likelihood for impaired glucose regulation in patients with non-alcoholic fatty liver disease. Type 2 diabetes mellitus is known to be associated with older age, a fact that reflects the long process for clinical onset of diabetes mellitus [14]. It can be assumed that metabolic derangements associated with non-alcoholic fatty liver disease and insulin resistance [17, 18] impose a stress on pancreatic β -cells that may eventually fail to compensate for the increased insulin requirements. In our study, the acute insulin response to the oral glucose load, which can be considered as a marker of β -cell function [19, 20], was found to be decreased in non-alcoholic fatty liver disease patients with hyperglycemia.

Higher BMI is also a known risk factor for type 2 diabetes mellitus [21]. In our study higher BMI independently predicted the risk for the presence of hyperglycemia among patients with non-alcoholic fatty liver disease [17]. More than half of our study population had a BMI below the threshold of 30 kg/m² though. Therefore, our findings should not be interpreted as if only obese patients with non-alcoholic fatty liver disease have hyperglycemia.

Serum levels of HDL-C were also lower in the subgroup of patients with hyperglycemia of the non-alcoholic fatty liver disease patients evaluated in our study. Low HDL-C is a characteristic finding in diabetic dyslipidemia and is also associated with prediabetes, insulin resistance, metabolic syndrome, and non-alcoholic fatty liver disease [20, 22–24]. The elevated levels of serum triglycerides, another feature of diabetic dyslipidemia, did not seem to differ between the non-alcoholic fatty liver disease patients who had hyperglycemia compared with those who did not, in our study. Also, comparison of the two groups on the basis of the ratio triglycerides/HDL-C, a parameter that has been associated with insulin resistance and atherogenicity [25, 26], showed only a marginal difference (Table 1).

Additionally, in our study, the non-alcoholic fatty liver disease patients with hyperglycemia had lower levels of serum albumin compared with those without hyperglycemia, although this difference was not independent of age, BMI, and HDL-C. Presumably, lower serum albumin in patients with non-alcoholic fatty liver disease could also be related to more advanced liver disease, higher degree of systemic inflammation, or albuminuria due to diabetic nephropathy [8, 27].

Screening for hyperglycemia could be considered in patients with non-alcoholic fatty liver disease given the strong association of this disorder with IGT, including diabetes mellitus. There are known risk factors for type 2 diabetes to guide the selection of patients to screen [12]. Age above 45 years and the association of a BMI above 25 kg/m² with HDL-C below 35 mg/dL are among the indicators for screening for type 2 diabetes proposed by the American Diabetes Association [12]. In our study, age, BMI, and HDL were independent indicators for the presence of impaired glucose regulation in patients with non-alcoholic fatty liver disease who had no known derangement in glucose metabolism.

If our patients had undergone assessment of fasting serum glucose alone, 25 of the 74 (33.8%) patients with diabetic or non-diabetic hyperglycemia and 4 of the 29 (13.8%) patients with, specifically, diabetic hyperglycemia would have been identified. In contrast, 70 of the 74 (94.6%) patients with diabetic or non-diabetic hyperglycemia and all of the 29 patients with, specifically, diabetic hyperglycemia were identified on the basis of the 2-hour serum glucose value obtained after an oral glucose tolerance test (Figure 1). Considerable discordance in the accuracy of fasting and 2-hour postload glucose for the identification of impaired glucose regulation has been observed in different populations [13, 28]. Fasting glucose may have lower sensitivity in younger individuals [13]. Additionally, IFG and IGT may more accurately reflect hepatic and muscle insulin resistance, respectively [14]. Yet, non-alcoholic fatty liver disease is associated with both hepatic and peripheral insulin resistance [29–31].

The oral glucose tolerance test is thought to be rather cumbersome to perform in everyday clinical practice [14]. Our study indicates that non-alcoholic fatty liver disease patients of older age, higher BMI, and lower HDL-C should be prioritized in this regard. In two other similar studies, older age and higher BMI have been associated with abnormal oral glucose tolerance in young male non-alcoholic fatty liver disease patients in China [32], and lower HDL-C has been associated with diabetes mellitus in non-alcoholic fatty liver disease patients in Hong Kong [33]. Besides, increased age and BMI are risk factors for more severe disease or adverse prognosis in patients with non-alcoholic fatty liver disease [2, 8, 9].

According to our findings, the value of an oral glucose tolerance test, if performed in patients with non-alcoholic fatty liver disease with appropriate risk factors, would be first to identify those with diabetic hyperglycemia. This group should be managed as for type 2 diabetes, if the diagnosis is confirmed with a second positive relevant test.

An oral glucose tolerance test in selected patients with non-alcoholic fatty liver disease can also identify those with impaired glucose tolerance, which indicates an increased risk for developing type 2 diabetes. Although the risk for developing type 2 diabetes can also be determined by considering patient characteristics that are more readily available [34], the presence of impaired glucose regulation signals additionally an increased risk for the development of macrovascular complications [35]. Non-alcoholic fatty liver disease patients with impaired glucose tolerance should be encouraged to modify lifestyle factors (e.g., lose weight and increase physical activity) to prevent the development of type 2 diabetes [14]. These measures would be also important for preventing the progression of liver disease [36].

Some of the patients with impaired glucose tolerance and additional risk factors for type 2 diabetes could also be candidates to receive pharmacologic therapy, particularly with metformin [14]. Pioglitazone might also be effective in this regard [37]. These insulin-sensitizing agents have additionally shown promise for the treatment of biopsy-proven non-alcoholic steatohepatitis in small clinical trials [38, 39]. Whether non-alcoholic fatty liver disease patients with impaired glucose tolerance represent appropriate candidates to receive such medications, on top of lifestyle modification, with the aim to prevent progression into type 2 diabetes and to non-alcoholic steatohepatitis and, also, to decrease the overall cardiovascular risk, requires further study.

In conclusion, in our study of patients with non-alcoholic fatty liver disease, older age, higher BMI, and lower serum levels of HDL-C independently predicted the presence of hyperglycemia (defined as IFG, IGT, or type 2 diabetes) that was primarily identified through an oral glucose tolerance test. Conclusively, we suggest that oral glucose tolerance testing should be considered for patients with non-alcoholic fatty liver disease with one or more of the above-mentioned predictor factors for hyperglycemia to readily diagnose and manage disorders of glucose metabolism.

Conflict of interests

The authors declare that they have no conflict of interests.

References

- [1] G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani, "Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study," *Hepatology*, vol. 42, no. 1, pp. 44–52, 2005.
- [2] L. A. Adams, J. F. Lymp, J. S. Sauver et al., "The natural history of nonalcoholic fatty liver disease: a population-based cohort study," *Gastroenterology*, vol. 129, no. 1, pp. 113–121, 2005.
- [3] N. Rafiq, C. Bai, Y. Fang et al., "Long-term follow-up of patients with nonalcoholic fatty liver," *Clinical Gastroenterology and Hepatology*, vol. 7, no. 2, pp. 234–238, 2009.
- [4] N. Stefan, K. Kantartzis, and H. U. Häring, "Causes and metabolic consequences of fatty liver," *Endocrine Reviews*, vol. 29, no. 7, pp. 939–960, 2008.
- [5] H. C. Pinto, A. Baptista, M. E. Camilo, A. Valente, A. Saragoça, and M. C. De Moura, "Nonalcoholic steatohepatitis:

- clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients," *Digestive Diseases and Sciences*, vol. 41, no. 1, pp. 172–179, 1996.
- [6] E. E. Powell, W. G. E. Cooksley, R. Hanson, J. Searle, J. W. Halliday, and L. W. Powell, "The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years," *Hepatology*, vol. 11, no. 1, pp. 74–80, 1990.
 - [7] K. Kantartzis, J. MacHann, F. Schick, A. Fritsche, H. U. Häring, and N. Stefan, "The impact of liver fat vs visceral fat in determining categories of prediabetes," *Diabetologia*, vol. 53, no. 5, pp. 882–889, 2010.
 - [8] P. Angulo, J. M. Hui, G. Marchesini et al., "The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD," *Hepatology*, vol. 45, no. 4, pp. 846–854, 2007.
 - [9] J. W. Haukeland, Z. Konopski, P. Linnestad et al., "Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease," *Scandinavian Journal of Gastroenterology*, vol. 40, no. 12, pp. 1469–1477, 2005.
 - [10] F. Angelico, M. Del Ben, R. Conti et al., "Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease," *Journal of Clinical Endocrinology and Metabolism*, vol. 90, no. 3, pp. 1578–1582, 2005.
 - [11] K. Kantartzis, F. Schick, H. U. Häring, and N. Stefan, "Environmental and genetic determinants of fatty liver in humans," *Digestive Diseases*, vol. 28, no. 1, pp. 169–178, 2010.
 - [12] "Screening for type 2 diabetes," *Diabetes Care*, vol. 27, pp. S11–S14, 2004.
 - [13] K. Borch-Johnsen, "Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data," *British Medical Journal*, vol. 317, no. 7155, pp. 371–375, 1998.
 - [14] D. M. Nathan, M. B. Davidson, R. A. DeFronzo et al., "Impaired fasting glucose and impaired glucose tolerance: implications for care," *Diabetes Care*, vol. 30, no. 3, pp. 753–759, 2007.
 - [15] S. Genuth, K. G. M. M. Alberti, P. Bennett et al., "Follow-up report on the diagnosis of diabetes mellitus," *Diabetes Care*, vol. 26, no. 11, pp. 3160–3167, 2003.
 - [16] J. C. Levy, D. R. Matthews, and M. P. Hermans, "Correct homeostasis model assessment (HOMA) evaluation uses the computer program," *Diabetes Care*, vol. 21, no. 12, pp. 2191–2192, 1998.
 - [17] H. J. Kim, H. J. Kim, K. E. Lee et al., "Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults," *Archives of Internal Medicine*, vol. 164, no. 19, pp. 2169–2175, 2004.
 - [18] G. Marchesini, M. Brizi, A. M. Morselli-Labate et al., "Association of nonalcoholic fatty liver disease with insulin resistance," *American Journal of Medicine*, vol. 107, no. 5, pp. 450–455, 1999.
 - [19] K. W. Chen, E. J. Boyko, R. W. Bergstrom et al., "Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM: 5-year follow-up of initially nondiabetic Japanese-American men," *Diabetes Care*, vol. 18, no. 6, pp. 747–753, 1995.
 - [20] S. M. Haffner, M. P. Stern, H. P. Hazuda, B. D. Mitchell, and J. K. Patterson, "Cardiovascular risk factors in confirmed prediabetic individuals," *Journal of the American Medical Association*, vol. 263, no. 21, pp. 2893–2898, 1990.
 - [21] P. W. Sullivan, E. H. Morrato, V. Ghushchyan, H. R. Wyatt, and J. O. Hill, "Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S. 2000–2002," *Diabetes Care*, vol. 28, no. 7, pp. 1599–1603, 2005.
 - [22] G. Marchesini, M. Brizi, G. Bianchi et al., "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome," *Diabetes*, vol. 50, no. 8, pp. 1844–1850, 2001.
 - [23] T. O'Brien, T. T. Nguyen, and B. R. Zimmerman, "Hyperlipidemia and diabetes mellitus," *Mayo Clinic Proceedings*, vol. 73, no. 10, pp. 969–976, 1998.
 - [24] K. Kantartzis, K. Rittig, A. Cegan et al., "Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions," *Diabetes Care*, vol. 31, no. 2, pp. 366–368, 2008.
 - [25] R. Boizel, P. Y. Benhamou, B. Lardy, F. Laporte, T. Foulon, and S. Halimi, "Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels," *Diabetes Care*, vol. 23, no. 11, pp. 1679–1685, 2000.
 - [26] T. McLaughlin, F. Abbasi, K. Cheal, J. Chu, C. Lamendola, and G. Reaven, "Use of metabolic markers to identify overweight individuals who are insulin resistant," *Annals of internal medicine*, vol. 139, no. 10, pp. 802–809, 2003.
 - [27] A. J. Sanyal, "AGA technical review on nonalcoholic fatty liver disease," *Gastroenterology*, vol. 123, no. 5, pp. 1705–1725, 2002.
 - [28] H. J. Woerle, W. P. Pimenta, C. Meyer et al., "Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values," *Archives of Internal Medicine*, vol. 164, no. 15, pp. 1627–1632, 2004.
 - [29] S. Deivanayagam, B. S. Mohammed, B. E. Vitola et al., "Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents," *American Journal of Clinical Nutrition*, vol. 88, no. 2, pp. 257–262, 2008.
 - [30] V. T. Samuel, Z. X. Liu, X. Qu et al., "Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease," *Journal of Biological Chemistry*, vol. 279, no. 31, pp. 32345–32353, 2004.
 - [31] A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., "Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities," *Gastroenterology*, vol. 120, no. 5, pp. 1183–1192, 2001.
 - [32] J. W. Yun, Y. K. Cho, J. H. Park et al., "Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease," *Liver International*, vol. 29, no. 4, pp. 525–529, 2009.
 - [33] V. W. S. Wong, A. Y. Hui, S. W. C. Tsang et al., "Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease," *Alimentary Pharmacology and Therapeutics*, vol. 24, no. 8, pp. 1215–1222, 2006.
 - [34] P. W. F. Wilson, J. B. Meigs, L. Sullivan, C. S. Fox, D. M. Nathan, and R. B. D'Agostino, "Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study," *Archives of Internal Medicine*, vol. 167, no. 10, pp. 1068–1074, 2007.
 - [35] J. H. Fuller, M. J. Shipley, and G. Rose, "Coronary heart disease risk and impaired glucose tolerance. The Whitehall Study," *Lancet*, vol. 1, no. 8183, pp. 1373–1376, 1980.
 - [36] K. Promrat, D. E. Kleiner, H. M. Niemeier et al., "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis," *Hepatology*, vol. 51, no. 1, pp. 121–129, 2010.
 - [37] A. H. Xiang, R. K. Peters, S. L. Kjos et al., "Effect of pioglitazone on pancreatic β -cell function and diabetes risk

- in Hispanic women with prior gestational diabetes,” *Diabetes*, vol. 55, no. 2, pp. 517–522, 2006.
- [38] G. P. Aithal, J. A. Thomas, P. V. Kaye et al., “Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis,” *Gastroenterology*, vol. 135, no. 4, pp. 1176–1184, 2008.
- [39] A. Uygun, A. Kadayifci, A. T. Isik et al., “Metformin in the treatment of patients with non-alcoholic steatohepatitis,” *Alimentary Pharmacology and Therapeutics*, vol. 19, no. 5, pp. 537–544, 2004.